JP Morgan Chase
BMRN icon

JP Morgan Chase’s BioMarin Pharmaceuticals BMRN Stock Holding History

JP Morgan Chase’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.64M Hold
30,000
– – ﹤0.01% 4259
2025
Q4 		$1.78M Buy
+30,000
New +$1.63M ﹤0.01% 4166
2024
Q3 		– Sell
-18,300
Closed -$1.51M – 7422
2024
Q2 		$1.51M Buy
+18,300
New +$1.52M ﹤0.01% 3993
2023
Q3 		– Sell
-53,900
Closed -$4.67M – 7470
2023
Q2 		$4.67M Buy
53,900
+27,600
+105% +$2.6M ﹤0.01% 2922
2023
Q1 		$2.56M Hold
26,300
– – ﹤0.01% 3359
2022
Q4 		$2.72M Buy
+26,300
New +$2.47M ﹤0.01% 3326
2022
Q3 		– Sell
-50,000
Closed -$4.14M – 6466
2022
Q2 		$4.14M Buy
50,000
+49,800
+24,900% +$3.97M ﹤0.01% 2952
2022
Q1 		$15K Buy
+200
New +$16.7K ﹤0.01% 6121
2021
Q2 		– Sell
-50,000
Closed -$3.78M – 6347
2021
Q1 		$3.78M Sell
50,000
-78,800
-61% -$6.44M ﹤0.01% 3212
2020
Q4 		$11.3M Buy
128,800
+38,300
+42% +$3.04M ﹤0.01% 2111
2020
Q3 		$6.88M Buy
90,500
+50,000
+123% +$5.06M ﹤0.01% 2314
2020
Q2 		$5M Buy
+40,500
New +$4.03M ﹤0.01% 2459
2020
Q1 		– Sell
-27,000
Closed -$2.28M – 5309
2019
Q4 		$2.28M Buy
27,000
+12,000
+80% +$906K ﹤0.01% 3293
2019
Q3 		$1.01M Sell
15,000
-105,000
-88% -$8.09M ﹤0.01% 3824
2019
Q2 		$10.1M Buy
+120,000
New +$10.3M ﹤0.01% 2103
2019
Q1 		– Sell
-289,300
Closed -$24.6M – 5765
2018
Q4 		$24.6M Buy
289,300
+180,000
+165% +$17.1M 0.01% 1326
2018
Q3 		$10.6M Sell
109,300
-700
-0.6% -$69.9K ﹤0.01% 2156
2018
Q2 		$10.4M Buy
110,000
+60,000
+120% +$5.25M ﹤0.01% 2117
2018
Q1 		$4.05M Hold
50,000
– – ﹤0.01% 2755
2017
Q4 		$4.46M Buy
+50,000
New +$4.35M ﹤0.01% 2771
2017
Q1 		– Sell
-40,000
Closed -$3.31M – 5048
2016
Q4 		$3.31M Buy
+40,000
New +$3.44M ﹤0.01% 2749
2016
Q3 		– Sell
-50,000
Closed -$3.89M – 4542
2016
Q2 		$3.89M Buy
+50,000
New +$4.25M ﹤0.01% 2442

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's BMRN Position: Q1 2026 in Review

JP Morgan Chase increased its BioMarin Pharmaceuticals (BMRN) stake by 21% in Q1 2026, buying an estimated $5.7M and bringing the position to 557,836 shares worth $30.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1720.

JP Morgan Chase first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $590M in Q4 2015. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • JP Morgan Chase held 557,836 shares of BioMarin Pharmaceuticals worth $30.6M as of Q1 2026.
  • JP Morgan Chase bought 97,831 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $5.7M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1720 holding.
  • JP Morgan Chase first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's BioMarin Pharmaceuticals position peaked at $590M in Q4 2015.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.